```
     (FILE 'HOME' ENTERED AT 10:14:39 ON 19 APR 2005)

     FILE 'CAPLUS' ENTERED AT 10:14:56 ON 19 APR 2005
L1              STRUCTURE UPLOADED
                S L1

     FILE 'REGISTRY' ENTERED AT 10:15:13 ON 19 APR 2005
L2            17 S L1

     FILE 'CAPLUS' ENTERED AT 10:15:13 ON 19 APR 2005
L3            24 S L2
L4            18 S L3 AND PY<2000

     FILE 'STNGUIDE' ENTERED AT 10:18:55 ON 19 APR 2005

     FILE 'CAPLUS' ENTERED AT 10:27:07 ON 19 APR 2005
                S L1

     FILE 'REGISTRY' ENTERED AT 10:27:55 ON 19 APR 2005
L5          4151 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:27:59 ON 19 APR 2005
L6          1275 S L5 FULL
L7            33 S L6 AND AROMATIC?
L8           421 S L6 AND (BENZENE OR PHENYL OR ARYL?)
L9           292 S L8 AND PY<2000
L10          141 S L9 AND ( O OR S)
L11             STRUCTURE UPLOADED
                S L1

     FILE 'REGISTRY' ENTERED AT 10:39:15 ON 19 APR 2005
L12           17 S L1

     FILE 'CAPLUS' ENTERED AT 10:39:15 ON 19 APR 2005
L13           24 S L12
                S L1

     FILE 'REGISTRY' ENTERED AT 10:39:28 ON 19 APR 2005
L14         4151 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:39:31 ON 19 APR 2005
L15         1275 S L14 FULL
L16          421 S L5 AND (BENZENE OR PHENYL OR ARYL?)
L17          970 S L6 AND PY<2000
L18           15 S L7 AND ( O OR S)
L19           15 S L18 AND AROMAT?
L20             STRUCTURE UPLOADED
                S L20

     FILE 'REGISTRY' ENTERED AT 10:46:08 ON 19 APR 2005
L21            5 S L20

     FILE 'CAPLUS' ENTERED AT 10:46:09 ON 19 APR 2005
L22            5 S L21
                S L20

     FILE 'REGISTRY' ENTERED AT 10:49:05 ON 19 APR 2005
L23          116 S L20 FULL

     FILE 'CAPLUS' ENTERED AT 10:49:07 ON 19 APR 2005
L24           20 S L23 FULL

     FILE 'STNGUIDE' ENTERED AT 10:52:07 ON 19 APR 2005

=>
```

>
Uploading C:\Program Files\Stnexp\Queries\1471b.str

L20 STRUCTURE UPLOADED

=> d
L20 HAS NO ANSWERS
L20 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l20
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

=> d 1-20 ibib abs hitstr

L24 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:18820 CAPLUS
DOCUMENT NUMBER: 140:107491
TITLE: Use of extenders in the tethering method of identifying compounds which modulate enzyme activity
INVENTOR(S): Erlanson, Daniel A.; Mcdowell, Robert S.; Hansen, Stig
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 121,216.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004005632	A1	20040108	US 2003-374499	20030225
US 6335155	B1	20020101	US 1998-105372	19980626
US 2002022233	A1	20020221	US 2001-981547	20011017
EP 1441228	A1	20040728	EP 2004-8373	20011120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2003104471	A1	20030605	US 2002-43833	20020111
US 6811966	B2	20041102		
US 2002081621	A1	20020627	US 2002-82046	20020220
US 2002155505	A1	20021024	US 2002-121216	20020410
CA 2478398	AA	20031023	CA 2003-2478398	20030226
WO 2003087054	A2	20031023	WO 2003-US6217	20030226
WO 2003087054	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1497450	A2	20050119	EP 2003-746539	20030226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004043426	A1	20040304	US 2003-465368	20030618

PRIORITY APPLN. INFO.:

US 1998-105372	A3	19980626
US 2000-252294P	P	20001121
US 2001-981547	A2	20011017
US 2002-121216	A2	20020410
US 2002-377034P	P	20020501
EP 2001-995216	A3	20011120
US 2001-990421	A3	20011121
US 2002-43833	A1	20020111
US 2003-374499	A	20030225
WO 2003-US6217	W	20030226

OTHER SOURCE(S): MARPAT 140:107491
AB The present invention relates to the use of extender compds. in the "tethering" method to identify compds. that modulate enzymic activity. Thus, the method was applied to protein tyrosine phosphatase 1B (PTP 1B). The method comprised (a) providing a PTP 1B having a reactive thiol located outside of the active site, (b) contacting the PTP 1B with an extender to form a PTP 1B-extender complex in which the extender comprises a first functionality that forms a covalent bond with the reactive thiol and a second functionality that is capable of forming a disulfide bond, (c) contacting the PTP 1B-extender complex with a candidate ligand that comprises a group that is capable of forming a disulfide bond with the

second functionality, (d) forming a disulfide bond between the PTP 1B-extender complex and the candidate ligand to form a PTP 1B-extender-ligand conjugate, and (e) identifying the candidate ligand present in the PTP 1B-extender-ligand conjugate. The examples include syntheses of numerous extenders.

IT **537708-00-2P 614760-05-3P 614760-07-5P**
614760-08-6P 614760-09-7P 614760-10-0P
614760-11-1P 614760-12-2P 614760-13-3P
614760-16-6P 614760-17-7P 614760-18-8P
614760-28-0P 643021-08-3P 643021-11-8P
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of extenders in tethering method of identifying compds. which modulate enzyme activity)

RN 537708-00-2 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-05-3 CAPLUS
CN L-α-Asparagine, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-07-5 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-08-6 CAPLUS
CN L-α-Asparagine, N-[[(2-aminoethyl)dithio]acetyl]-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 614760-09-7 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1R)-2-[(2-aminoethyl)dithio]-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-10-0 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1S)-2-[(2-aminoethyl)dithio]-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-11-1 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-12-2 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1S)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-13-3 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[2-[2-[(acetylthio)methyl]-4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-16-6 CAPLUS
CN L-Phenylalaninamide, N-acetyl-L-seryl-N-[4-[([1,1'-biphenyl]-3-ylsulfonyl)amino]butyl]-4-[(carboxycarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-17-7 CAPLUS

CN β-Alaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-[4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 614760-18-8 CAPLUS
CN β-Alaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-(2-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-28-0 CAPLUS
CN Butanoic acid, 3-amino-4-[[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-08-3 CAPLUS
CN Acetic acid, [[4-[(2R)-2-[[(2S)-2-(acetylamino)-3-hydroxy-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-11-8 CAPLUS
CN D-Phenylalaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-N-[3-[[[2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

IT **614760-27-9P 614760-30-4P 614760-35-9P**
614760-37-1P 614760-38-2P 614760-39-3P
614760-42-8P 614760-52-0P 643021-05-0P
643021-06-1P 643021-07-2P 643021-10-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(use of extenders in tethering method of identifying compds. which modulate enzyme activity)
RN 614760-27-9 CAPLUS
CN Butanoic acid, 4-[[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]amino]-3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-30-4 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-35-9 CAPLUS
CN Butanoic acid, 4-[[(1R)-2-(acetylthio)-1-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]amino]-3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-37-1 CAPLUS
CN 5,6-Dithia-2,9,12-triazatridecanedioic acid, 8-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]-11-[2-(1,1-dimethylethoxy)-2-oxoethyl]-10-oxo-, 1-(1,1-dimethylethyl) 13-(9H-fluoren-9-ylmethyl) ester, (8R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-38-2 CAPLUS
CN 14-Oxa-5,6-dithia-2,9-diazahexadecanoic acid, 11-amino-8-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]-15,15-dimethyl-10,13-dioxo-, 1,1-dimethylethyl ester, (8R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-39-3 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1R)-2-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]dithio]-1-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-42-8 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-

[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-52-0 CAPLUS
CN L-Phenylalaninamide, N-acetyl-O-(1,1-dimethylethyl)-L-seryl-N-(4-aminobutyl)-4-[[(1,1-dimethylethoxy)oxoacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-05-0 CAPLUS
CN Acetic acid, [[4-[(2R)-2-[[(2S)-3-(1,1-dimethylethoxy)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-06-1 CAPLUS
CN Acetic acid, [[4-[(2R)-2-[[(2S)-2-amino-3-(1,1-dimethylethoxy)-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-07-2 CAPLUS
CN Acetic acid, [[4-[(2R)-2-[[(2S)-2-(acetylamino)-3-(1,1-dimethylethoxy)-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 643021-10-7 CAPLUS
CN D-Phenylalaninamide, N-acetyl-O-(1,1-dimethylethyl)-L-seryl-N-(3-aminopropyl)-4-[[(1,1-dimethylethoxy)oxoacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:841814 CAPLUS
DOCUMENT NUMBER: 140:73029
TITLE: Identification of a monoacid-based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B
AUTHOR(S): Xin, Zhili; Liu, Gang; Abad-Zapatero, Cele; Pei, Zhonghua; Szczepankiewicz, Bruce G.; Li, Xiaofeng; Zhang, Tianyuan; Hutchins, Charles W.; Hajduk, Philip J.; Ballaron, Stephen J.; Stashko, Michael A.; Lubben, Thomas H.; Trevillyan, James M.; Jirousek, Michael R.
CORPORATE SOURCE: Global Pharmaceutical Research and Development, Metabolic Disease Research, Abbott Laboratories, Abbott Park, IL, 60064-6098, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(22), 3947-3950
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Monoacid-based PTP1B inhibitors with improved physiochem. properties have been investigated. A (2-hydroxy-phenoxy) acetic acid-based phosphotyrosyl

mimetic has been linked with an optimized second arylphosphate binding site ligand to produce a compound with low micromolar potency against PTP1B, good selectivity over TCPTP (20-fold) and high cell permeability in the Caco-2 system.

IT **641636-59-1**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(preparation and Caco-2 cell permeability and structure-activity relationships of monoacid-based phosphotyrosine mimetics as protein tyrosine phosphatase 1B-selective inhibitors)

RN 641636-59-1 CAPLUS

CN Benzoic acid, 2-[4-[[(2S)-2-(acetylamino)-3-[4-[(carboxycarbonyl)amino]phenyl]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **474917-55-0P**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and Caco-2 cell permeability and structure-activity relationships of monoacid-based phosphotyrosine mimetics as protein tyrosine phosphatase 1B-selective inhibitors)

RN 474917-55-0 CAPLUS

CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:837043 CAPLUS
DOCUMENT NUMBER: 139:338191
TITLE: Methods for identifying compounds that modulate enzymatic activity
INVENTOR(S): Erlanson, Daniel A.; McDowell, Robert S.; Hansen, Stig
PATENT ASSIGNEE(S): Sunesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087054	A2	20031023	WO 2003-US6217	20030226
WO 2003087054	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002155505	A1	20021024	US 2002-121216	20020410
US 2004005632	A1	20040108	US 2003-374499	20030225
CA 2478398	AA	20031023	CA 2003-2478398	20030226
EP 1497450	A2	20050119	EP 2003-746539	20030226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:	US 2002-121216	A	20020410
	US 2002-377034P	P	20020501
	US 2003-374499	A	20030225
	US 1998-105372	A3	19980626
	US 2000-252294P	P	20001121
	US 2001-981547	A2	20011017
	US 2001-990421	A3	20011121
	WO 2003-US6217	W	20030226

OTHER SOURCE(S): MARPAT 139:338191

GI



I

AB The invention relates to the use of "tethering" to identify compds. that modulate enzymic activity. The method comprises (a) providing a protein tyrosine phosphatase (PTP) having a reactive thiol located outside of the active site, (b) contacting the PTP with an extender to form a PTP-extender complex in which the extender comprises a first functionality that forms a covalent bond with the reactive thiol and a second functionality that is capable of forming a disulfide bond, (c) contacting the PTP-extender complex with a candidate ligand that comprises a group that is capable of forming a disulfide bond with the second functionality, (d) forming a disulfide bond between the PTP-extender complex and the candidate ligand to form a PTP-extender-ligand conjugate, and (e) identifying the candidate ligand present in the PTP-extender-ligand conjugate. The examples include syntheses of compds. of the invention, including that of peptide extender mol. I.

IT **537708-00-2P 614760-05-3P 614760-07-5P**
614760-08-6P 614760-09-7P 614760-10-0P
614760-11-1P 614760-12-2P 614760-13-3P
614760-14-4P 614760-15-5P 614760-16-6P
614760-17-7P 614760-18-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compound synthesis in methods for identifying compds. that modulate enzymic activity)

RN 537708-00-2 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-05-3 CAPLUS
CN L-α-Asparagine, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-07-5 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-08-6 CAPLUS
CN L-α-Asparagine, N-[[(2-aminoethyl)dithio]acetyl]-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 614760-09-7 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1R)-2-[(2-aminoethyl)dithio]-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-10-0 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1S)-2-[(2-aminoethyl)dithio]-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-11-1 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-12-2 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1S)-2-(acetylthio)-1-[[4-[(carboxycarbonyl)amino]phenyl]methyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-13-3 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[2-[2-[(acetylthio)methyl]-4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-14-4 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2R)-2-(acetylamino)-3-hydroxy-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-15-5 CAPLUS
CN L-Phenylalaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-N-[3-[[[2-[3-(trifluoromethyl)phenyl]-4-thiazolyl]carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 614760-16-6 CAPLUS
CN L-Phenylalaninamide, N-acetyl-L-seryl-N-[4-[([1,1'-biphenyl]-3-ylsulfonyl)amino]butyl]-4-[(carboxycarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-17-7 CAPLUS
CN β-Alaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-[4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 614760-18-8 CAPLUS
CN β-Alaninamide, N-acetyl-L-seryl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-(2-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **614760-27-9P 614760-28-0P 614760-30-4P**
614760-35-9P 614760-37-1P 614760-38-2P
614760-39-3P 614760-42-8P 614760-47-3P
614760-48-4P 614760-49-5P 614760-51-9P
614760-52-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compound synthesis in methods for identifying compds. that modulate enzymic activity)
RN 614760-27-9 CAPLUS
CN Butanoic acid, 4-[[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]amino]-3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-28-0 CAPLUS
CN Butanoic acid, 3-amino-4-[[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-30-4 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[2-[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-35-9 CAPLUS
CN Butanoic acid, 4-[[(1R)-2-(acetylthio)-1-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]amino]-3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-37-1 CAPLUS
CN 5,6-Dithia-2,9,12-triazatridecanedioic acid, 8-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]-11-[2-(1,1-dimethylethoxy)-2-oxoethyl]-10-oxo-, 1-(1,1-dimethylethyl) 13-(9H-fluoren-9-ylmethyl) ester, (8R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-38-2 CAPLUS
CN 14-Oxa-5,6-dithia-2,9-diazahexadecanoic acid, 11-amino-8-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]-15,15-dimethyl-10,13-dioxo-, 1,1-dimethylethyl ester, (8R,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-39-3 CAPLUS
CN L-α-Asparagine, N-(1-oxo-2-propenyl)-β-alanyl-N-[(1R)-2-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]dithio]-1-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]-, 1,1-dimethylethyl

ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-42-8 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[(1R)-2-(acetylthio)-1-[[4-[[(1,1-dimethylethoxy)oxoacetyl]amino]phenyl]methyl]ethyl]-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-47-3 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2S)-3-(1,1-dimethylethoxy)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-48-4 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2S)-2-amino-3-(1,1-dimethylethoxy)-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-49-5 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2S)-2-(acetylamino)-3-(1,1-dimethylethoxy)-1-oxopropyl]amino]-3-hydroxypropyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-51-9 CAPLUS
CN L-Phenylalaninamide, N-acetyl-O-(1,1-dimethylethyl)-L-seryl-N-(3-aminopropyl)-4-[[(1,1-dimethylethoxy)oxoacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 614760-52-0 CAPLUS
CN L-Phenylalaninamide, N-acetyl-O-(1,1-dimethylethyl)-L-seryl-N-(4-aminobutyl)-4-[[(1,1-dimethylethoxy)oxoacetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:298265 CAPLUS

DOCUMENT NUMBER: 139:17112
TITLE: Discovery of a New Phosphotyrosine Mimetic for PTP1B Using Breakaway Tethering
AUTHOR(S): Erlanson, Daniel A.; McDowell, Robert S.; He, Molly M.; Randal, Mike; Simmons, Robert L.; Kung, Jenny; Waight, Andrew; Hansen, Stig K.
CORPORATE SOURCE: Sunesis Pharmaceuticals Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of the American Chemical Society (2003), 125(19), 5602-5603
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Protein tyrosine phosphatases play important roles in many signaling cascades involved in human disease. The identification of drug-like inhibitors for these targets is a major challenge, and the discovery of suitable phosphotyrosine (pY) mimetics remains one of the key difficulties. Here we describe an extension of tethering technol., "breakaway tethering", which is ideally suited for discovering such new chemical entities. The approach involves first irreversibly modifying a protein with an extender that contains both a masked thiol and a known pY mimetic. The extender is then cleaved to release the pY mimetic, unmasking the thiol. The resulting protein is screened against a library of disulfide-containing small mol. fragments; any mols. with inherent affinity for the pY binding site will preferentially form disulfides with the extender, allowing for their identification by mass spectrometry. The ability to start from a known substrate minimizes perturbation of protein structure and increases the opportunity to probe the active site using tethering. We applied this approach to the anti-diabetic protein PTP1B to discover a pY mimetic which belongs to a new mol. class and which binds in a novel fashion.

IT **537708-00-2**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering)
RN 537708-00-2 CAPLUS
CN L-Serinamide, N-(bromoacetyl)-β-alanyl-N-[2-[4-[(carboxycarbonyl)amino]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:928230 CAPLUS
DOCUMENT NUMBER: 138:19472
TITLE: Method of identifying inhibitors of Cdc25 using three dimensional crystal structure of the catalytic domain of Cdc25
INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David; Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro; Robinson, Simon; Eckstein, Jens; Haupt, Andreas; Walker, Nigel; Dixon, Richard W.; Choquette, Deborah;

Blanchard, Jill; Kluge, Arthur; Pal, Kollol; Bockovich, Nicholas; Come, Jon; Hediger, Mark

PATENT ASSIGNEE(S): Australia

SOURCE: U.S. Pat. Appl. Publ., 246 pp., Cont.-in-part of U.S. Ser. No. 645,750.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002183249	A1	20021205	US 2001-797500	20010301
PRIORITY APPLN. INFO.:			US 1999-172215P P	19990831
			US 2000-645750 A2	20000824

OTHER SOURCE(S): MARPAT 138:19472

AB The present invention relates to the x-ray crystallog. study of proteins comprising the catalytic domains of Cdc25. The atomic coordinates which result from this study are of use in identifying compds. which fit in the catalytic domain and are, therefore, potential inhibitors of Cdc25. The present invention further provides proteins which comprise the ligand binding domain of Cdc25, crystalline forms of these proteins and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compds. which inhibit the binding of a native substrate to the Cdc25 catalytic domain. These Cdc25 inhibitors are of use in methods of treating a patient having a condition which is modulated by Cdc25 activity, for example, a condition characterized by excessive, inappropriate or undesirable cellular proliferation such as cancer.

IT **329276-13-3P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of identifying inhibitors of Cdc25 using three dimensional crystal structure of catalytic domain of Cdc25)

RN 329276-13-3 CAPLUS

CN L-Norvalinamide, N-[(2-ethoxy-1-naphthalenyl)carbonyl]-4-[(ethoxyoxoacetyl)amino]-L-phenylalanyl-L-norvalyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-[2-methyl-1-(1-methylethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L24 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:869580 CAPLUS
DOCUMENT NUMBER: 137:353320
TITLE: Preparation of amino(oxo)acetic acid derivatives as selective protein tyrosine phosphatase inhibitors
INVENTOR(S): Liu, Gang; Xin, Zhili; Pei, Zhonghua; Li, Xiaofeng; Szczepankiewicz, Bruce G.; Janowick, David A.; Oost, Thorsten K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Pat. Appl. 2002 72,516.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002169157	A1	20021114	US 2002-85157	20020227
US 2002035137	A1	20020321	US 2001-918928	20010731
US 2002072516	A1	20020613	US 2001-941471	20010829
WO 2003072537	A2	20030904	WO 2003-US3663	20030206
WO 2003072537	A3	20031218		

W: CA, JP, MX
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

US 2000-228651P	P	20000829
US 2000-650922	A2	20000829
US 2001-918928	A2	20010731
US 2001-941471	A2	20010829
US 2002-85157	A	20020227

OTHER SOURCE(S): MARPAT 137:353320

AB Compds. B-L-A-N(D)COCO2P2 [A are rings of defined structure; B = H, alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; D = substituted Ph, alkyl, or 1-alkenyl [the substituent at the o- or 2-position is alkoxy, alkyl, sulfamoyl, amino, cyano, nitro, CO2P1, SO3H, P(O)(OH)2, CH2P(O)(OH)2, CHFP(O)(OH)2, CF2P(O)(OH)2, or C(:NH)NH2] or certain 5-membered heterocycles; P1, P2 = H, alkyl, alkenyl, arylalkyl, cycloalkyl, cycloalkylalkyl; L = (un)substituted (hetero)alkylene] or their therapeutically acceptable salts were prepared as protein tyrosine kinase 1B (PTP1B) inhibitors. Thus, N-[5-[[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl]amino]pentanoyl]-L-methionine and Me 2-[4-[[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl]amino]-3-ethylphenylalanyl)amino]butoxy]-6-hydroxybenzoate were prepared and showed Kic = 0.077 ± 0.012 and 0.016 ± 0.003 μM,

resp., for inhibition of PTP1B.

IT **474917-56-1P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino(oxo)acetic acid derivs. as selective protein tyrosine phosphatase inhibitors)

RN 474917-56-1 CAPLUS

CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **474917-55-0P 474917-57-2P 474917-58-3P 474917-60-7P 474917-61-8P 474917-62-9P 474917-64-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino(oxo)acetic acid derivs. as selective protein tyrosine phosphatase inhibitors)

RN 474917-55-0 CAPLUS

CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-57-2 CAPLUS

CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]butoxy]-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-58-3 CAPLUS
CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]butoxy]-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-60-7 CAPLUS
CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-61-8 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[4-(3-hydroxy-2-nitrophenoxy)butyl]amino]-2-[(methoxycarbonyl)amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-62-9 CAPLUS
CN Benzoic acid, 2-[4-[[(2S)-3-[4-[(carboxycarbonyl)amino]phenyl]-2-[(methoxycarbonyl)amino]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-64-1 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[4-[2-(acetylamino)-3-hydroxyphenoxy]butyl]amino]-2-[(methoxycarbonyl)amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **474917-93-6P 474917-94-7P 474917-96-9P**
474917-98-1P 474918-00-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino(oxo)acetic acid derivs. as selective protein tyrosine phosphatase inhibitors)

RN 474917-93-6 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[[oxo(phenylmethoxy)acetyl]amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-94-7 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[[oxo(phenylmethoxy)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-96-9 CAPLUS
CN Benzoic acid, 2-[4-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[4-[[oxo(phenylmethoxy)acetyl]amino]phenyl]propyl]amino]butoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474917-98-1 CAPLUS
CN L-Phenylalanine, N-(methoxycarbonyl)-4-[[oxo(phenylmethoxy)acetyl]amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474918-00-8 CAPLUS
CN L-Phenylalanine, N-(methoxycarbonyl)-4-[[oxo(phenylmethoxy)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:754385 CAPLUS
DOCUMENT NUMBER: 137:279359
TITLE: Preparation of isoquinuclidine derivatives as antidiabetics
INVENTOR(S): Tomiyama, Hiroshi; Kobayashi, Yoshinori; Noda, Atsushi
PATENT ASSIGNEE(S): Kotobuki Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076981	A1	20021003	WO 2002-JP2847	20020325
W: AU, BR, CA, CN, ID, IN, JP, KR, MX, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2441838	AA	20021003	CA 2002-2441838	20020325
EP 1375500	A1	20040102	EP 2002-708653	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
BR 2002006436	A	20040706	BR 2002-6436	20020325
US 2004067911	A1	20040408	US 2003-467719	20030812

PRIORITY APPLN. INFO.: JP 2001-88653 A 20010326
WO 2002-JP2847 W 20020325

OTHER SOURCE(S): CASREACT 137:279359; MARPAT 137:279359

AB Title compds Q-A1-CHR1CHR2R3 [Q = isoquinuclidin-2-yl, A1 = CH2, CO; R1 = H, Me; R2 = Ph-A2-(CH2)n; n = 0, 1, 2, 3; A2 = single bond, O; R3 = carboxyl, alkoxycarbonyl, alkylthiocarbonyl, aminocarbonyl, amino, etc.] and their pharmaceutically acceptable salts, useful as antidiabetics, are prepared Thus, reaction of 4(R)-benzyl-3-N-(2-carboxymethyl-3-phenylpropanoyl)-2-oxazolidinone with isoquinuclidine hydrochloride in THF and DMF in the presence of diethylphosphoryl cyanide and triethylamine gave 4(R)-benzyl-3-N-(2-isoquinuclidinecarbonylmethyl-3-phenylpropanoyl)-2-oxazolidinone, which was treated with 30% H1O2 and LiOH in THF and H2O to give (2S)-2-benzyl-4-(isoquinuclidin-2-yl)-4-oxobutanoic acid (I). I showed hypoglycemic activity in rats at 10 mg/kg orally.

IT **465527-09-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinuclidine derivs. as antidiabetics)

RN 465527-09-7 CAPLUS
CN Acetic acid, [[4-[2-[[(1R)-3-(2-azabicyclo[2.2.2]oct-2-yl)-3-oxo-1-(phenylmethyl)propyl]amino]-2-oxoethyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:696111 CAPLUS
DOCUMENT NUMBER: 137:228607
TITLE: Crystal structure and three-dimensional structure of human Cdc25 catalytic domains and its use in designing peptidomimetic inhibitors
INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David;

Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro; Robinson, Simon; Eckstein, Jens; Haupt, Andreas; Walker, Nigel; Dixon, Richard W.; Choquette, Deborah; Blanchard, Jill; Kluge, Arthur; Pal, Kollol; Bockovich, Nicholas; Come, Jon; Hediger, Mark

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany; GPC Biotech Inc.

SOURCE: PCT Int. Appl., 351 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070680	A1	20020912	WO 2001-US6587	20010301

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2001-US6587 20010301

OTHER SOURCE(S): MARPAT 137:228607

AB Due to its role in regulating the cell cycle, Cdc25 (a family of dual specificity phosphatases) is a potential target for therapies aimed at controlling proliferative diseases, but rational, structure-based design has not been possible because of the lack of accurate 3-dimensional data. The present invention relates to polypeptides which comprises the ligand binding domain of human Cdc25 proteins, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the 3-dimensional structure of the catalytic domain of Cdc25. In particular, a high resolution crystal structure was obtained for the polypeptide denoted CDC25B(ΔN8B), comprising residues Glu-368 through Arg-562 of human Cdc25B, complexed with a pentapeptide inhibitor denoted cdc1249 (2-methoxynaphthyl-1-carboxy-(4-sulfomethyl)-L-Phe-L-Glu-L-Glu-L-naphthylalanine-L-Glu-amide). The invention also relates to the use of the 3-dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compds. which inhibitors of Cdc25 activity, for example, compds. which inhibit the binding of a native substrate to the Cdc25 catalytic domain. The syntheses and structures of a large number of putative pentapeptide inhibitors are also provided. Such inhibitors have potential in the treatment of diseases associated with excessive cellular proliferation, such as cancer, restenosis, reocclusion of coronary artery, and inflammation.

IT **457889-14-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(crystal structure and three-dimensional structure of human Cdc25 catalytic domains and its use in designing peptidomimetic inhibitors)

RN 457889-14-4 CAPLUS

CN L-Norvalinamide, N-[(2-ethoxy-1-naphthalenyl)carbonyl]-4-[(ethoxyoxoacetyl)amino]-L-phenylalanyl-L-norvalyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:51438 CAPLUS
DOCUMENT NUMBER: 136:118447
TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6448281	B2	20020910		
CA 2412718	AA	20020117	CA 2001-2412718	20010704
EP 1301487	A2	20030416	EP 2001-951274	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502761	T2	20040129	JP 2002-509292	20010704
US 6479508	B1	20021112	US 2001-995099	20011127
CA 2439176	AA	20020912	CA 2002-2439176	20020306
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1370682	A2	20031217	EP 2002-712681		20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004520839	T2	20040715	JP 2002-570761		20020306
US 2003232816	A1	20031218	US 2002-238282		20020910
US 6794404	B2	20040921			
US 2004110126	A1	20040610	US 2004-471164		20040205
US 2004224955	A1	20041111	US 2004-851710		20040521
PRIORITY APPLN. INFO.:			US 2000-216084P	P	20000706
			US 2001-274374P	P	20010308
			US 2001-281343P	P	20010405
			US 2001-898297	A3	20010703
			WO 2001-CA989	W	20010704
			US 2001-995099	A3	20011127
			WO 2002-CA323	W	20020306
			US 2002-238282	A1	20020910

OTHER SOURCE(S): MARPAT 136:118447

GI



I

AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H , alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepared Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 μM.

IT **390810-84-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390810-84-1 CAPLUS

CN L-Phenylalanine, 4-[(carboxycarbonyl)amino]-N-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L24 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:833296 CAPLUS
DOCUMENT NUMBER: 135:357916
TITLE: Para-amino substituted phenylamide glucokinase activators
INVENTOR(S): Bizzarro, Fred Thomas; Haynes, Nancy-Ellen; Sarabu, Ramakanth
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-g., Switz.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001085707	A1	20011115	WO 2001-EP4859		20010430
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2407763	AA	20011115	CA 2001-2407763		20010430
BR 2001010703	A	20030128	BR 2001-10703		20010430
EP 1283830	A1	20030219	EP 2001-943302		20010430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003532719	T2	20031105	JP 2001-582308		20010430
US 2001051731	A1	20011213	US 2001-846820		20010501
US 6489485	B2	20021203			
US 2003060625	A1	20030327	US 2002-255440		20020926
ZA 2002008503	A	20040122	ZA 2002-8503		20021021
PRIORITY APPLN. INFO.:			US 2000-202389P	P	20000508
			WO 2001-EP4859	W	20010430
			US 2001-846820	A3	20010501

OTHER SOURCE(S): MARPAT 135:357916

AB Para-alkyl, aryl, cycloheteroalkyl or heteroaryl [carbonyl or sulfonyl] amino substituted Ph amides active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes were studied. Seventeen title compds. were prepared via standard methods and their glucokinase activation activities were measured. All compds. had an SC1.5 equal to or less than 30 μM. Among the compds. prepared were 95% N-{4-[2-cyclopentyl-1-(2-thiazolylcarbamoyl)ethyl]phenyl}benzamide and 72% Me 6-(3-cyclopentyl-2-{4-[(3-pyridinecarbonyl)amino]phenyl}propionylamino) nicotinate.

IT **372938-06-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and use of antidiabetic p-amino substituted phenylamide glucokinase activators)

RN 372938-06-2 CAPLUS
CN Acetic acid, [[4-[1-(cyclopentylmethyl)-2-oxo-2-(2-thiazolylamino)ethyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:168124 CAPLUS
DOCUMENT NUMBER: 134:218936
TITLE: Crystal structure of CDC25 proteins and its use in rational design of inhibitors
INVENTOR(S): Taylor, Neil R.; Borhani, David; Epstein, David; Rudolph, Johannes; Ritter, Kurt; Fujimori, Taro; Robinson, Simon; Eckstein, Jens; Haupt, Andreas; Walker, Nigel; Dixon, Richard W.; Choquette, Deborah; Blanchard, Jill; Kluge, Arthur; Pal, Kollol; Bockovich, Nicholas; Come, Jon; Hediger, Mark
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 314 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016300	A2	20010308	WO 2000-US23473	20000825
WO 2001016300	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383603	AA	20010308	CA 2000-2383603	20000825
EP 1226237	A2	20020731	EP 2000-959449	20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-172215P P 19990831
WO 2000-US23473 W 20000825
OTHER SOURCE(S): MARPAT 134:218936

AB The present invention relates to polypeptides which comprise the ligand binding domain of CDC25, crystalline forms of these polypeptides, and the use of these crystalline forms to determine the 3-dimensional structure of the catalytic domain of CDC25 alone and in complexes with pentapeptide inhibitors. Atomic coordinates are provided from x-ray diffraction of crystals of CDC25A and CDC25B catalytic domains in the presence and absence of various inhibitors. The invention also relates to the use of the 3-dimensional structure of the CDC25 catalytic domain in methods of designing and/or identifying potential inhibitors of CDC25 activity, for example, compds. which inhibit the binding of a native substrate to the CDC25 catalytic domain. The method comprises the steps of (1) identifying one or more functional groups capable of interacting with one or more subsites of the CDC25 catalytic domain, and (2) identifying a scaffold which presents the

functional group or functional groups in a suitable orientation for interacting with one or more subsites of the CDC25 catalytic domain. Since CDC25 is a potential target for therapies aimed at controlling proliferative disease, the atomic coordinates allow rational structure-based design of potential agents for the treatment of cancer, restenosis, reocclusion of coronary artery, or inflammation.

IT **329276-13-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure of CDC25 proteins and its use in rational design of inhibitors)

RN 329276-13-3 CAPLUS

CN L-Norvalinamide, N-[(2-ethoxy-1-naphthalenyl)carbonyl]-4-[(ethoxyoxoacetyl)amino]-L-phenylalanyl-L-norvalyl-L-prolyl-3-benzo[b]thien-3-yl-L-alanyl-5-carboxy-N-[2-methyl-1-(1-methylethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L24 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:98505 CAPLUS

DOCUMENT NUMBER: 132:137119

TITLE: Preparation of N-substituted sulfonamide derivatives for potentiating glutamate receptor function

INVENTOR(S): Arnold, Macklin Brian; Jones, Winton Dennis; Ornstein, Paul Leslie; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 206 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006537	A1	20000210	WO 1999-US17017	19990728
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952355	A1	20000221	AU 1999-52355	19990728
US 6525099	B1	20030225	US 2001-744419	20010123
PRIORITY APPLN. INFO.:			US 1998-94921P P	19980731
			WO 1999-US17017 W	19990728

OTHER SOURCE(S): MARPAT 132:137119
GI



I



II

AB Title compds. (I) [wherein Ra = alkyl, acyl, CO2(aryl)alkyl, CO2(alkyl)aryl, C(O)CH2OH, or N-substituted aminoacyl; R1 = (un)substituted naphthyl, Ph, furyl, thienyl, or pyridyl; R2 = (cyclo)alkyl, haloalkyl, alkenyl, alkoxyalkyl, heteroarom., (un)substituted Ph, etc.; R5-R8 = independently H, (aryl)alkyl, (aryl)alkenyl, aryl, or 2 of R5-R8 together with the C atom(s) to which they are attached form a carbocyclic ring and the remaining R5-R8 = H] were prepared as ampakines (no data) for the treatment of a wide variety of psychiatric conditions and neurol. disorders. Examples include prepns. of over 100 intermediates and 281 invention compds. For instance, reaction of 2-(4-bromophenyl)propylamine.HCl (2-step preparation given) with MeSO2Cl in toluene and 10% aqueous NaOH gave N-2-(4-bromophenylpropyl) methanesulfonamide (81%). Arylation of the sulfonamide with 3-formylbenzeneboronic acid in the presence of K2CO3 and Pd(PPh3)4 in toluene gave II in 41% yield.

IT **257299-24-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(product; preparation of N-substituted sulfonamide derivs. as glutamate receptor potentiators for the treatment of psychiatric conditions and neurol. disorders)

RN 257299-24-4 CAPLUS
CN Acetic acid, [[4-[1-methyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:404935 CAPLUS
DOCUMENT NUMBER: 131:59136
TITLE: Pyridones as Src family SH2 domain inhibitors
INVENTOR(S): Betageri, Rajashekhar; Beaulieu, Pierre L.; Llinas-Brunet, Montse; Ferland, Jean-Marie; Cardozo, Mario; Moss, Neil; Patel, Usha; Proudfoot, John R.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9931066	A1	19990624	WO 1998-US26123		19981209
W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SK, TR, UA, UZ, VN					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2315113	AA	19990624	CA 1998-2315113		19981209
AU 9917194	A1	19990705	AU 1999-17194		19981209
US 6054470	A	20000425	US 1998-208113		19981209
EP 1045836	A1	20001025	EP 1998-962022		19981209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO					
JP 2003514762	T2	20030422	JP 2000-538993		19981209
ZA 9811570	A	19990916	ZA 1998-11570		19981217
US 6268365	B1	20010731	US 1999-438629		19991112
US 6284768	B1	20010904	US 1999-438647		19991112
US 6156784	A	20001205	US 1999-455633		19991207
PRIORITY APPLN. INFO.:			US 1997-69971P	P	19971218
			US 1998-208113	A3	19981209
			WO 1998-US26123	W	19981209
			US 1999-129414P	P	19990415

OTHER SOURCE(S): MARPAT 131:59136

AB Compds. A-Q-NB-CH(D-NH-E)-CH2-a-R-C (ring a is selected from cycloalkyl, aryl, heterocyclyl; A = alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, heterocyclyl, aryl; Q = CO, SO2, C:S; B = H, alkyl, a nitrogen-protecting group; R = bond, alkyl, aryl, heterocyclyl, cycloalkyl linker; C is an acidic functionality that carries one or two neg. charges at physiol. pH; D = CH2, CO, C:S; E are certain six-membered unsatd. heterocycles) were prepared These compds. possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands. Thus, 3-[2'(S)-(1''''-naphthylacetyl)amino-3'-[4''-(1'''-carboxy-1'''-methylethyl)benzene]propanoylamino]-1-(4-methoxybenzyl)-4-methyl-2-pyridone was prepared and showed IC50 = 96 μM for blocking IL-2 production in human blood CD4 pos. T-lymphocytes after T cell receptor and CD28 crosslinking.

IT **228407-72-5P 228407-73-6P 228407-74-7P**
228407-75-8P 228407-77-0P 228407-78-1P
228407-79-2P 228407-81-6P 228407-82-7P
228407-83-8P 228407-84-9P 228407-85-0P

228407-90-7P 228407-93-0P 228407-95-2P
228407-96-3P 228407-97-4P 228407-98-5P
228407-99-6P 228408-00-2P 228408-01-3P
228408-02-4P 228408-03-5P 228408-04-6P
228408-05-7P 228408-06-8P 228408-07-9P
228408-08-0P 228408-11-5P 228408-15-9P
228408-16-0P 228408-17-1P 228408-20-6P
228408-70-6P 228408-71-7P 228408-72-8P
228408-73-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridones as Src family SH2 domain inhibitors)

RN 228407-72-5 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-73-6 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[(1H-indol-3-ylacetyl)amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-74-7 CAPLUS
CN Acetic acid, [[4-[(2S)-2-(acetylamino)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-75-8 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2-benzothiazolylamino)carbonyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-77-0 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(1-naphthalenylamino)carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-78-1 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-79-2 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2-amino-4-phenyl-5-thiazolyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-81-6 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[2-(formylamino)-4-thiazolyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-82-7 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[[2-[[(4-chlorophenyl)sulfonyl]amino]-4-thiazolyl]carbonyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-83-8 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(5-methyl-2-phenyl-4-thiazolyl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-84-9 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(5-methyl-2-phenyl-4-oxazolyl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-85-0 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxo-2-[[(2-pyrazinyl-4-

thiazolyl)acetyl]amino]propyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-90-7 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-(dimethylamino)phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-93-0 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(methyl-1-naphthalenylamino)carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-95-2 CAPLUS

CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(5-hydroxy-1H-indol-3-yl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-96-3 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(2-methyl-1H-indol-3-yl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-97-4 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(3,4-dihydro-2(1H)-isoquinolinyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-98-5 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[(2-methyl-1-naphthalenyl)amino]carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228407-99-6 CAPLUS
CN L-Phenylalaninamide, N-(2-carboxybenzoyl)glycyl-4-[(carboxycarbonyl)amino]-N-[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-00-2 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[(2-naphthalenylacetyl)amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-01-3 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(4-nitrophenyl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-02-4 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(2-nitrophenyl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-03-5 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[2-(dimethylamino)phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-04-6 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(4-bromophenyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-05-7 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(3-bromophenyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-06-8 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[(2-bromophenyl)acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-07-9 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-08-0 CAPLUS
CN Acetic acid, [[4-[(2S)-2-[[[4-(diethylamino)phenyl]acetyl]amino]-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-11-5 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-(1-methylethyl)phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-15-9 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-[(1-methylethyl)amino]phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-16-0 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-[(2,2-dimethylpropyl)amino]phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-17-1 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[3-(dimethylamino)phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-20-6 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[(1-naphthalenylacetyl)amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-70-6 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxo-2-[(phenylacetyl)amino]propyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-71-7 CAPLUS

CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-72-8 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[[4-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228408-73-9 CAPLUS
CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(3-nitrophenyl)acetyl]amino]-3-oxopropyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **228411-65-2P 228411-66-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyridones as Src family SH2 domain inhibitors)

RN 228411-65-2 CAPLUS

CN Acetic acid, [[4-[(2S)-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228411-66-3 CAPLUS

CN Acetic acid, [[4-[(2S)-2-amino-3-[[1,2-dihydro-1-[(4-methoxyphenyl)methyl]-4-methyl-2-oxo-3-pyridinyl]amino]-3-oxopropyl]phenyl]amino]oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:261309 CAPLUS

DOCUMENT NUMBER: 131:67637
TITLE: Ligands for the Tyrosine Kinase p56lck SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate Replacements
AUTHOR(S): Beaulieu, Pierre L.; Cameron, Dale R.; Ferland, Jean-Marie; Gauthier, Jean; Ghiro, Elise; Gillard, James; Gorys, Vida; Poirier, Martin; Rancourt, Jean; Wernic, Dominik; Llinas-Brunet, Montse; Betageri, Raj; Cardozo, Mario; Hickey, Eugene R.; Ingraham, Richard; Jakes, Scott; Kabcenell, Alisa; Kirrane, Tom; Lukas, Susan; Patel, Usha; Proudfoot, John; Sharma, Rajiv; Tong, Liang; Moss, Neil
CORPORATE SOURCE: Bio-Mega Research Division, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Journal of Medicinal Chemistry (1999), 42(10), 1757-1766
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB P56lck is a member of the src family of tyrosine kinases. Through modular binding units called SH2 domains, p56lck promotes phosphotyrosine-dependent protein-protein interactions and plays a critical role in signal transduction events that lead to T-cell activation. Starting from the phosphorylated dipeptide (I), a high-affinity ligand for the p56lck SH2 domain, novel dipeptides were designed that contain monocharged, nonhydrolyzable phosphate group replacements and bind to the protein with KD's in the low micromolar range. Replacement of the phosphate group in phosphotyrosine-containing sequences by a (R/S)-hydroxyacetic or an oxamic acid moiety leads to hydrolytically stable, monocharged ligands, with 83- and 233-fold decreases in potency, resp. This loss in binding affinity can be partially compensated for by incorporating large lipophilic groups at the inhibitor N-terminus. These groups provide up to 13-fold increases in potency depending on the nature of the phosphate replacement. The discovery of potent (2-3 μM), hydrolytically stable dipeptide derivs., bearing only two charges at physiol. pH, represents a significant step toward the discovery of compds. with cellular activity and the development of novel therapeutics for conditions associated with undesired T-cell proliferation.

IT **229171-43-1P 229171-44-2P 229171-45-3P**
229171-46-4P 229171-47-5P 229171-48-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design and preparation of dipeptide derivs. as ligands for binding to tyrosine kinase p56lck SH2 domain)

RN 229171-43-1 CAPLUS

CN L-α-Glutamine, N-acetyl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-44-2 CAPLUS
CN L-α-Glutamine, N-benzoyl-4-[(carboxycarbonyl)amino]-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-45-3 CAPLUS
CN L-α-Glutamine, 4-[(carboxycarbonyl)amino]-N-(phenylacetyl)-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-46-4 CAPLUS
CN L-α-Glutamine, 4-[(carboxycarbonyl)amino]-N-(1-oxo-3-phenylpropyl)-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-47-5 CAPLUS
CN L-α-Glutamine, 4-[(carboxycarbonyl)amino]-N-(2-naphthalenylacetyl)-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-48-6 CAPLUS
CN L-α-Glutamine, 4-[(carboxycarbonyl)amino]-N-(1-naphthalenylacetyl)-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **229171-78-2P 229171-79-3P 229171-80-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design and preparation of dipeptide derivs. as ligands for binding to tyrosine kinase p56lck SH2 domain)
RN 229171-78-2 CAPLUS
CN L-α-Glutamine, 4-[[oxo(phenylmethoxy)acetyl]amino]-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 229171-79-3 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[(methoxyoxoacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229171-80-6 CAPLUS
CN L-α-Glutamine, N-[(1,1-dimethylethoxy)carbonyl]-4-[(methoxyoxoacetyl)amino]-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:705724 CAPLUS
DOCUMENT NUMBER: 123:256432
TITLE: Milbemycin derivatives as anthelmintics
INVENTOR(S): Morisawa, Yasuhiro; Saito, Akio; Toyama, Toshimitsu; Kaneko, Susumu
PATENT ASSIGNEE(S): Sankyo Co., Ltd., USA; Ciba Geigy Corp.
SOURCE: U.S., 62 pp. Cont.-in-part of U.S. Ser. No. 951,310, abandoned.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5428034	A	19950627	US 1993-71765	19930609
US 5686484	A	19971111	US 1995-396662	19950301

PRIORITY APPLN. INFO.:

JP 1988-220235	A	19880902
US 1989-400888	B1	19890830
JP 1990-50761	A	19900301
US 1991-661856	B1	19910227
US 1992-951310	B2	19920924
US 1993-71765	A3	19930609

OTHER SOURCE(S): MARPAT 123:256432

AB 13-Aralkoxymilbemycins (177 compds.) were prepared for use as anthelmintics. Thus, 5-oxo-13-hydroxymilbemycin A4 was converted to the 13-iodo analog which was treated with 3-nitrocinnamyl alc. and reduced to give 13-(3-aminocinnamyloxy)milbemycin A4. The latter compound was reductively methylated with paraformaldehyde to give 13-(3-methylaminocinnamyloxy)milbemycin A4, which had 100% anthelmintic activity at 0.125 mg/kg orally in rats.

IT **128829-99-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and anthelmintic activity of 13-aralkoxymilbemycins)

RN 128829-99-2 CAPLUS
CN Milbemycin B, 5-O-demethyl-28-deoxy-6,28-epoxy-25-ethyl-13-[2-[4-[(methoxyoxoacetyl)amino]phenyl]ethoxy]-, (6R,13R,25R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L24 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:214908 CAPLUS
DOCUMENT NUMBER: 116:214908
TITLE: Preparation of (amidinoheterocyclylmethyl)amino acid sulfonamides and related compounds as thrombin inhibitors
INVENTOR(S): Ackerman, Jean; Banner, David; Gubernator, Klaus; Hadvary, Paul; Hilpert, Kurt; Mueller, Klaus; Labler, Ludvik; Schmid, Gerard; Tschopp, Thomas; et al.

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 468231	A2	19920129	EP 1991-110928	19910702
EP 468231	A3	19920401		
EP 468231	B1	19940921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2044636	AA	19920106	CA 1991-2044636	19910614
US 5260307	A	19931109	US 1991-719429	19910624
ZA 9105028	A	19920325	ZA 1991-5028	19910628
AU 9179490	A1	19920109	AU 1991-79490	19910701
AU 650458	B2	19940623		
HU 58288	A2	19920228	HU 1991-2206	19910701
HU 217815	B	20000428		
JP 04230363	A2	19920819	JP 1991-185774	19910701
JP 07030022	B4	19950405		
IL 98690	A1	19960514	IL 1991-98690	19910701
IL 112712	A1	19960912	IL 1991-112712	19910701
ES 2061125	T3	19941201	ES 1991-110928	19910702
NO 9102626	A	19920106	NO 1991-2626	19910704
NO 177704	B	19950731		
NO 177704	C	19951108		
KR 218600	B1	19990901	KR 1991-11300	19910704
FI 9103282	A	19920106	FI 1991-3282	19910705
FI 102966	B1	19990331		
US 5393760	A	19950228	US 1993-77476	19930615
US 5532232	A	19960702	US 1994-343168	19941122
US 5595999	A	19970121	US 1995-473060	19950607
US 5583133	A	19961210	US 1995-511428	19950804
FI 9601629	A	19960412	FI 1996-1629	19960412
FI 105474	B1	20000831		
US 5763436	A	19980609	US 1996-715038	19960917

PRIORITY APPLN. INFO.:

CH 1990-2250	A	19900705
CH 1991-1315	A	19910502
US 1991-719429	A3	19910624
IL 1991-98690	A3	19910701
FI 1991-3282	A	19910705
US 1993-77476	A3	19930615
US 1994-343168	A3	19941122
US 1995-473060	A3	19950607

OTHER SOURCE(S): MARPAT 116:214908
GI



I

AB Title compds. [I; R, R3 = (hetero)aryl, heterocyclyl; T = CH2, O; L = NH, O; N(X)M = N(SO2R3)CH2, (substituted) isoquinolinylene; X = H, CH2CO2H, alkoxycarbonylmethyl, alkyleneiminocarbonylmethyl, (alkylated) CH2CONH2; M = R1CH2CH, R1COCH2CH, PhCH2O2CNHCH2CH, etc.; R1 = (hetero)aryl, heterocyclyl, cycloalkyl], were prepared Thus, tert-Bu R-4-hydroxymethyl-

2,2-dimethyl-3-oxazolidinecarboxylate was successively tosylated, condensed with 2-indolinone using NaH in DMF, and treated with 2N HCl to give 1-[(R)-2-amino-3-hydroxypropyl]-2-indolinone. This was acylated with 2-naphthylsulfonyl chloride followed by Jones oxidation to give N-(2-naphthylsulfonyl)-3-(2,3-dioxo-1-indolinyl)-D-alanine. This was converted to (R)-N-[(RS)-1-aminido-3-piperidinylmethyl]-α-(2-naphthylsulfonamido-2,3-dioxo-1-indolinepropionamide acetate. The latter inhibited thrombin with Ki = 8.55 nM and trypsin with Ki = 20,075.

IT **140642-73-5P 140644-43-5P 140644-52-6P 140644-54-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as antithrombotic)

RN 140642-73-5 CAPLUS

CN Acetic acid, [[4-[3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]amino]-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]phenyl]amino]oxo-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140644-43-5 CAPLUS

CN Acetic acid, [[4-[3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]amino]-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]phenyl]amino]oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 140644-52-6 CAPLUS

CN Acetic acid, [[4-[3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]amino]-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]phenyl]amino]oxo-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 140644-54-8 CAPLUS
CN Acetic acid, [[4-[3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]amino]-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]phenyl]amino]oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L24 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:591060 CAPLUS
DOCUMENT NUMBER: 113:191060
TITLE: 13-Substituted milbemycin derivatives as insecticides, acaricides, and anthelmintics and their preparation
INVENTOR(S): Morisawa, Yasuhiro; Saito, Akio; Toyama, Toshimitsu; Kaneko, Susumu
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 357460	A2	19900307	EP 1989-308900	19890901
EP 357460	A3	19910109		
EP 357460	B1	19950118		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

AU 8940924	A1	19900308	AU 1989-40924		19890830
AU 613521	B2	19910801			
JP 02174780	A2	19900706	JP 1989-225878		19890831
JP 06067944	B4	19940831			
ZA 8906705	A	19910626	ZA 1989-6705		19890901
ES 2069589	T3	19950516	ES 1989-308900		19890901
CA 1339129	A1	19970729	CA 1989-610224		19890901
PRIORITY APPLN. INFO.:			JP 1988-220235	A	19880902
OTHER SOURCE(S):	MARPAT 113:191060				

GI



I

AB The title compds. I [R1, R2 = H, halo, NO2, (substituted) C1-4 alkyl, alkoxy; R5 = Me, Et, Me2CH, EtMeCH; X = OH, (substituted) C1-5 alkanoyloxy,hydroxyimino] useful as acaricides, insectides (no data) and anthelmintics are prepared A mixture of 5-oxo-13-phenethyloxymilbemycin A4, NH2OH.HCl, H2O, dioxane, and MeOH was stirred at 35° for 3 h to give 13-phenethyloxymilbemycin A4 5-oxime. At 0,250 mg/kg orally, 13-[2-(4-benzenesulfonylaminophenyl)ethoxy]milbemycin A4 gave complet control of Nippostongylus brasiliensis in rats.

IT **128829-99-2P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide, acaricide, and anthelmintic)

RN 128829-99-2 CAPLUS

CN Milbemycin B, 5-O-demethyl-28-deoxy-6,28-epoxy-25-ethyl-13-[2-[4-[(methoxyoxoacetyl)amino]phenyl]ethoxy]-, (6R,13R,25R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.